Sema4 Holdings Corp - Ordinary Shares - Class A Stock News

Sold 69,858 shares, reducing stake value by about $6.45 million Post-trade stake in GeneDx Holdings Corp: zero shares, $0 value The position previously comprised 1.9% of the fund's AUM as of the prior quarter

Sold 69,858 shares, reducing stake value by about $6.45 million Post-trade stake in GeneDx Holdings Corp: zero shares, $0 value The position previously comprised 1.9% of the fund's AUM as of the prior quarter

Added 120,000 shares of GeneDx Holdings, an increase valued at ~$12.93 million Post-trade stake: 120,000 shares worth $12.93 million as of September 30, 2025 GeneDx Holdings is not among Telemark Asset Management's top five positions by size

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: Stifel 2025 Healthcare Conference New York, New York Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET Jefferies Global Healthcare Conference London, UK Presentation: Wed...

GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Bryan Dechairo - Chief Operating Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Mark Mas...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2025.

GeneDx Holdings Corp. is poised for strong Q3 results, driven by expanding exome and genome testing in pediatric and neonatal settings. Key metrics for WGS include test volume growth and reimbursement rates, with management targeting a 30% annual volume increase and improving price realization. Consensus-beating revenue is likely if test volume growth accelerates and pricing improves, supported...